MovDisordV3, PubMed, Checkpoint, bibRecord, 003E85

Response to levodopa challenge in Tourette syndrome.

Identifieur interne : 003E85 ( PubMed/Checkpoint ); précédent : 003E84; suivant : 003E86

Response to levodopa challenge in Tourette syndrome.

Auteurs : K J Black [États-Unis] ; J W Mink

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.

RBID : pubmed:11104204

English descriptors

KwdEn :
- Adult, Carbidopa (administration & dosage), Carbidopa (adverse effects), Carbidopa (blood), Dopamine (blood), Dopamine (metabolism), Dopamine Agents (administration & dosage), Dopamine Agents (adverse effects), Dopamine Agents (blood), Drug Therapy, Combination, Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (blood), Male, Middle Aged, Pilot Projects, Severity of Illness Index, Single-Blind Method, Tourette Syndrome (blood), Tourette Syndrome (drug therapy), Tourette Syndrome (metabolism), Treatment Outcome.
MESH :
- chemical , administration & dosage : Carbidopa, Dopamine Agents, Levodopa.
- chemical , adverse effects : Carbidopa, Dopamine Agents, Levodopa.
- chemical , blood : Carbidopa, Dopamine, Dopamine Agents, Levodopa.
- chemical , metabolism : Dopamine.
- blood : Tourette Syndrome.
- drug therapy : Tourette Syndrome.
- metabolism : Tourette Syndrome.
- Adult, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Single-Blind Method, Treatment Outcome.

Abstract

A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.

PubMed: 11104204

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 003E61
to stream PubMed, to step Curation: 003E61

Links to Exploration step

pubmed:11104204

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Response to levodopa challenge in Tourette syndrome.</title>
<author><name sortKey="Black, K J" sort="Black, K J" uniqKey="Black K" first="K J" last="Black">K J Black</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Mink, J W" sort="Mink, J W" uniqKey="Mink J" first="J W" last="Mink">J W Mink</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:11104204</idno>
<idno type="pmid">11104204</idno>
<idno type="wicri:Area/PubMed/Corpus">003E61</idno>
<idno type="wicri:Area/PubMed/Curation">003E61</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003E85</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Response to levodopa challenge in Tourette syndrome.</title>
<author><name sortKey="Black, K J" sort="Black, K J" uniqKey="Black K" first="K J" last="Black">K J Black</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Mink, J W" sort="Mink, J W" uniqKey="Mink J" first="J W" last="Mink">J W Mink</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (blood)</term>
<term>Dopamine (blood)</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (blood)</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (blood)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Tourette Syndrome (blood)</term>
<term>Tourette Syndrome (drug therapy)</term>
<term>Tourette Syndrome (metabolism)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11104204</PMID>
<DateCreated><Year>2001</Year>
<Month>03</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted><Year>2001</Year>
<Month>05</Month>
<Day>31</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>15</Volume>
<Issue>6</Issue>
<PubDate><Year>2000</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Response to levodopa challenge in Tourette syndrome.</ArticleTitle>
<Pagination><MedlinePgn>1194-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText>A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Black</LastName>
<ForeName>K J</ForeName>
<Initials>KJ</Initials>
<AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mink</LastName>
<ForeName>J W</ForeName>
<Initials>JW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>NS01808</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>NS01898</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber>
<NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016037">Single-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005879">Tourette Syndrome</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year>
<Month>12</Month>
<Day>5</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2001</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2000</Year>
<Month>12</Month>
<Day>5</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11104204</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Missouri (État)</li>
</region>
<settlement><li>Saint-Louis (Missouri)</li>
</settlement>
<orgName><li>École de médecine (Université Washington de Saint-Louis)</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Mink, J W" sort="Mink, J W" uniqKey="Mink J" first="J W" last="Mink">J W Mink</name>
</noCountry>
<country name="États-Unis"><region name="Missouri (État)"><name sortKey="Black, K J" sort="Black, K J" uniqKey="Black K" first="K J" last="Black">K J Black</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E85 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003E85 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:11104204
   |texte=   Response to levodopa challenge in Tourette syndrome.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:11104204" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Response to levodopa challenge in Tourette syndrome.

Response to levodopa challenge in Tourette syndrome.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki